Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Revenio Group
5667 investors follow this company
BUY 30.70 LOWEST 29.90 VOLUME 37 132
SELL 30.75 HIGHEST 30.85 VALUE 1,132 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Latest reports

Extensive report

Analyytikko

Mikael Rautanen
+358 50 346 0321

Upcoming events

20
Feb
Tilinpäätöstiedotteet

Latest video

Latest insider trading

Type: stock_exchange_release
15.1.
2020

THE REVENIO ICARE IC200 INTRAOCULAR PRESSURE MEASUREMENT DEVICE HAS BEEN GRANTED MARKETING AUTHORIZATION IN THE UNITED STATES

Icare ic200, the new generation tonometer for intraocular pressure screening for professional use has been cleared by FDA, the Food and Drug Administration of the United States. The product has been previously authorized in both Europe and Japan. The FDA clearance now enables the launch of sales and marketing measures also in the United States.

Type: stock_exchange_release
7.1.
2020

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Pulkkinen Robin
Position: Chief Financial Officer
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20200107080215_2
____________________________________________

Type: stock_exchange_release
7.1.
2020

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Tammela Kari-Pekka
Position: Member of the Board/Deputy member
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20200107075519_2
____________________________________________

Type: stock_exchange_release
30.12.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Hildén Timo
Position: Chief Executive Officer
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191230134617_2
____________________________________________

Type: stock_exchange_release
23.12.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Hildén Timo
Position: Chief Executive Officer
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191223153227_2
____________________________________________

Type: stock_exchange_release
20.12.
2019

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Type: stock_exchange_release
19.12.
2019

NEW MEMBER APPOINTED TO REVENIO'S MANAGEMENT TEAM

Revenio Group Corporation has appointed Giuliano Barbaro, M.Sc.Eng. to its Management Team. Barbaro, who has worked as the Head of Ocular Imaging Device R&D at CenterVue S.p.A. since 2008, will join the Management Team on 1 January 2020.

Type: stock_exchange_release
13.12.
2019

REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2020

Type: stock_exchange_release
9.12.
2019

DRSplus, the newest addition to CenterVue's family of fundus imaging devices, has been approved by the Food and Drug Administration in the USA and CE certified in Europe. This means that the sales and marketing of the new product will start in 2019 in Europe and early 2020 in the United States. Revenio acquired CenterVue in April 2019.

Type: stock_exchange_release
27.11.
2019

Notice pursuant to chapter 9, section 5 of the securities market act 

Revenio Group Corporation has November 24, 2019 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that William Demant Invest A/S's share of the total number of shares and voting rights in Revenio Group Corporation has increased to more than five per cent.

William Demant Invest A/S now holds 2.192.838 shares in Revenio Group Corporation, which is 8.28 per cent of the company's shares and voting rights.

Revenio Group

Revenio lyhyesti

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio’s business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.